Navigation Links
Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics
Date:6/25/2012

GAITHERSBURG, Md., June 25, 2012 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has been awarded another NIH SBIR (Small Business Innovation Research) grant for developing its small interfering RNA (siRNA) therapeutic product STP705 to improve skin wound healing with minimized scar formation.  This funding will further enhance the company's effort for perfection of its nanoparticle-based siRNA delivery systems and speed up the IND enabling studies for STP705.  Sirnaomics' multi-targeted siRNA therapeutics utilizing its nanoparticle delivery technologies represents a unique approach for realizing the advantage of siRNA-based drugs. Since its establishment, Sirnaomics has been successfully awarded five NIH SBIR grants in addition to other government grant funding. 

Sirnaomics is a leading biopharmaceutical company in the discovery and development of siRNA therapeutics.  The company's mission is to advance siRNA therapeutics by using its proprietary multi-targeted siRNA design and screening together with nanoparticle-mediated siRNA delivery vehicles.  Through in-house efforts and collaborations, Sirnaomics has developed nanoparticle-based siRNA delivery systems in three generations: the self-assembled nanoparticles (1st), the ligand-directed nanoparticles (2nd)  and the infrared-activated nanoparticles (3rd), for various types of therapeutic applications.  Based on these two technology platforms, Sirnaomics has developed an enriched pipeline of siRNA therapeutic product candidates, including STP705 for improvement of skin wound healing with minimized scar formation, STP601 for treatment of ocular AMD/diabetic retinopathy, STP702 for treatment of respiratory influenza viral infection, STP909 for treatment of HPV infection/cervical cancer, and candidates for several other therapeutic indications. 

"Receiving an NIH SBIR grant for development of siRNA therapeutics to improve skin scarless wound healing clearly demonstrates the scientific merits of Sirnaomics' siRNA therapeutic program," said Dr. Patrick Y. Lu, President and CEO of the company. "The collaboration among scientists and clinicians from Sirnaomics, Johns Hopkins University and Navy Medical Research Center provided a solid foundation for the success of such a novel therapeutic approach." Dr. Lu further emphasized that continuous government funding is critical for the growth of a therapeutic product company like Sirnaomics, especially in the current financial environment.

According to a report from The Mattson Jack Group, market for reduction of scarring on skin is about US$4 billion a year. Some 42 million surgery-patients in the U.S. each year could potentially benefit from the pharmaceuticals that can improve wound healing and minimize scar formation. There are 41.8 million surgical procedures each year in Europe and 70 million procedures annually in the United States involving skin wounds, which could benefit from these pharmaceuticals.  Currently there is no approved pharmaceutical of such available in the market in either U.S. or Europe. Sirnaomics has discovered and developed its first-in-class siRNA therapeutic candidate, STP705, to address this unmet clinical need.  Currently, this novel drug compound is under intensive IND-enabling studies in both U.S. and China.

Sirnaomics, Inc. is a privately held Delaware corporation headquartered in Gaithersburg, Maryland, U.S.A. Established in 2007 by a group of leading scientists in the field of RNAi technology, the company is pursuing the mission of advancing RNAi technology with novel multi-targeted therapeutic development. In 2008, the company established its subsidiary in Suzhou, China to expand its R&D capacity and potential market. Members of the senior management team bring over 90 years of combined experience in the biopharmaceutical, financial and business management industries. Supported with funding from angel investors, corporate partnerships, government grants and venture capitals, Sirnaomics has developed a strong portfolio of intellectual properties with an enriched product pipeline. The therapeutic areas of interest include regenerative medicine (wound healing), diabetic complications, respiratory viral infection, HPV and cervical cancer, among others. CONTACT: George Ji, Senior VP for Corporate Developmentgji@sirnaomics.comSirnaomics, Inc.Tel: +1-301-740-1730Fax: +1-301-740-1731 www.sirnaomics.com


'/>"/>
SOURCE Sirnaomics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ReShape Medical Appoints Robert E. Grant to Board of Directors
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. Sorrento Therapeutics Awarded Third Phase I STTR Grant
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
6. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
7. QRxPharma Granted Additional US Patent on MoxDuo®
8. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
9. BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication
10. Broad Patent Protection Granted for iBio Immunomodulator
11. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016   HeartWare International, Inc ... call and webcast to discuss its financial results for ... on Thursday, February 25, 2016 at 8:00 a.m. ET. ... to the conference call and webcast.  On the conference ... results, highlights from the fourth quarter and business outlook.   ...
(Date:2/12/2016)... AUSTIN, Texas , Feb. 12, 2016 ... Institute for Robotic Surgery at St. David,s North Austin ... the da Vinci ® Xi ® Surgical ... ® 7000dV. Thiru Lakshman , M.D., ... performed a total proctocolectomy utilizing Integrated Table Motion technology, ...
(Date:2/12/2016)... North Carolina , 12 februari 2016 ... Inc. (AAI/CML), een toonaangevende leverancier van productie ... en biotechnologische industrieën, kondigt vandaag een uitbreiding ... mogelijkheden op haar locatie in ... vraag heeft geleid tot meerdere recente investeringen. ...
Breaking Medicine Technology:
(Date:2/14/2016)... ... February 14, 2016 , ... ... eating disorders professionals near their residence. The nature of the illnesses requires ongoing ... care or time allotted at work to make traditional appointments. These people struggle ...
(Date:2/13/2016)... ... , ... Hidden Cypress in Sun City is the place to be on March 3rd to ... Weniger will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting ... pricing on offers. In addition, prizes will be given away and light refreshments will be ...
(Date:2/13/2016)... ... ... Many individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and ... Fitness has delved into this niche allowing those giving up their beloved pasta a ... 30 grams of protein and only 7 grams of carbohydrates per 50 gram serving--a ...
(Date:2/13/2016)... ... February 13, 2016 , ... In its newly ... vein visualization technology should be used to ensure patient safety when placing an ... INS Standards mandate the use of vein visualization technology in patients with difficult ...
(Date:2/13/2016)... ... , ... In the early or “honeymoon” stage of a relationship, couples strive ... their way to be romantic, and may exaggerate a strength or two in an ... profile. , A recent study from Queendom.com , however, suggests that new ...
Breaking Medicine News(10 mins):